ABEONA THERAPEUTICS INC. Other Noncash Income (Expense)
ABEONA THERAPEUTICS INC. (ABEO) reported Other Noncash Income (Expense) of -$347.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-24.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2021-03-24
- ABEONA THERAPEUTICS INC. other noncash income (expense) for fiscal 2020 was -$347.00K.
- ABEONA THERAPEUTICS INC. other noncash income (expense) for fiscal 2019 was -$367.00K.
| Period end | Other Noncash Income (Expense) 12 month |
|---|---|
| 2020-12-31 | -$347.00K 10-K · filed 2021-03-24 |
| 2019-12-31 | -$367.00K 10-K · filed 2021-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |